NSAIDs for Bone Health

JS
Overseen ByJeffery Staab, MS
Age: 18 - 65
Sex: Any
Trial Phase: Phase 1
Sponsor: United States Army Research Institute of Environmental Medicine

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores how different non-steroidal anti-inflammatory drugs (NSAIDs) affect bones and muscles after exercise. The medications tested include Celecoxib (Celebrex), Flurbiprofen, and Ibuprofen, along with a placebo for comparison. The goal is to determine how a single dose of these drugs influences the body's bone and muscle processes post-workout. Individuals who exercise at least twice a week and are willing to adjust their supplement and medication use may be suitable for this study. As a Phase 1 trial, the research focuses on understanding how the treatment works in people.

Will I have to stop taking my current medications?

You will need to stop taking NSAIDs and similar medications during the study, except for those provided by the study team. The protocol does not specify about other medications, but you must stop using nutritional supplements, alcohol, and nicotine during each study period unless approved by the study team.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

A previous study found that ibuprofen was generally well-tolerated, but it may cause stomach issues or allergic reactions in people sensitive to aspirin. Celecoxib has been linked to a higher risk of serious heart problems, such as heart attacks and strokes. It may also cause bleeding in the stomach or intestines, sometimes without warning signs. Flurbiprofen can be harmful if swallowed or if it contacts the skin, and it might also irritate the skin or eyes. Each of these medications is already approved for other uses, providing some evidence of safety, but side effects can still occur. Always consult a healthcare provider to weigh the risks and benefits.12345

Why are researchers excited about this trial's treatments?

Researchers are excited about these treatments because they explore how different NSAIDs—like ibuprofen, celecoxib, and flurbiprofen—affect bone metabolism after exercise. Normally, NSAIDs are used to relieve pain and inflammation, but this trial aims to see if they also influence how bones respond to physical stress. Each NSAID might interact differently with bone tissues, offering insights into which one could potentially aid in faster recovery or improved bone health. This could lead to more personalized approaches in managing exercise-related bone stress, beyond just pain relief.

What evidence suggests that this trial's treatments could be effective for post-exercise bone and muscle metabolism?

This trial will compare the effects of ibuprofen, celecoxib, and flurbiprofen, each taken as a single dose before a plyometric exercise bout, with a placebo. Research has shown that taking ibuprofen before exercise doesn't significantly alleviate muscle soreness or enhance performance and might slow the body's natural healing process. Celecoxib, another treatment option in this trial, appears ineffective in reducing swelling or muscle damage after exercise. Flurbiprofen, also being tested, doesn't significantly impact soreness or recovery. Overall, studies suggest these medications might not effectively ease muscle issues after exercise.678910

Are You a Good Fit for This Trial?

Inclusion Criteria

You must be currently exercising at least twice a week.
You cannot take certain pain-relieving medications, such as aspirin or ibuprofen, unless specifically instructed by the study team.
Must be willing to discontinue the use of nutritional supplements, alcohol and nicotine during each study period (4 trials of 5 consecutive days each), unless approved by PI
See 1 more

Exclusion Criteria

You have a history of stomach ulcers.
You have a past injury in your back or shoulder that may get worse with exercise.
You have experienced stomach problems or discomfort in the past when taking drugs like aspirin or ibuprofen.
See 10 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants consume a single dose of NSAID or placebo and perform plyometric exercise

1 day
1 visit (in-person)

Follow-up

Participants are monitored for changes in circulating markers of bone and muscle metabolism

4 hours
1 visit (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Celecoxib
  • Flurbiprofen
  • Ibuprofen
  • Placebo
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Placebo Group
Group I: IbuprofenExperimental Treatment1 Intervention
Group II: FlurbiprofenExperimental Treatment1 Intervention
Group III: CelecoxibExperimental Treatment1 Intervention
Group IV: PlaceboPlacebo Group1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

United States Army Research Institute of Environmental Medicine

Lead Sponsor

Trials
67
Recruited
3,700+

Published Research Related to This Trial

Over a 10-year period, a total of 29,656,286 units of various ibuprofen formulations were sold in Poland, with only 5 spontaneous reports of adverse effects, indicating that ibuprofen is a very safe medication with rare side effects.
The study suggests that while ibuprofen is generally safe, the current monitoring system for adverse effects in Poland is insufficient and requires enhancements to better detect potential issues.
Safety of oral ibuprofen--analysis of data from the spontaneous reporting system in Poland.Kuchari, E., Han, S., Karłowicz-Bodalska, K., et al.[2022]
Ibuprofen is effective in managing pain and inflammation, but its use requires careful consideration in patients with certain conditions, such as renal disease and bleeding disorders, due to its effects on prostaglandins.
The drug can be safely used in various patient populations, including the elderly and those with specific diseases, but clinicians should be cautious when prescribing it alongside other medications like aspirin or warfarin, as interactions may occur.
Use of ibuprofen in unusual circumstances.Furst, DE.[2019]
Flurbiprofen has been proven safe and effective as an analgesic, anti-inflammatory, and antipyretic agent in numerous European clinical trials over the past 12 years, showing it is at least as potent as indomethacin and significantly more potent than aspirin.
In patients with rheumatoid arthritis and ankylosing spondylitis, flurbiprofen demonstrated superior or equivalent efficacy compared to other common treatments like aspirin, naproxen, and indomethacin, with minimal gastrointestinal side effects.
European experience with flurbiprofen. A new analgesic/anti-inflammatory agent.Buchanan, WW., Kassam, YB.[2022]

Citations

1.pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov/39044030/
A single, maximal dose of celecoxib, ibuprofen, or ...A single, maximal dose of celecoxib, ibuprofen, or flurbiprofen does not reduce the muscle signalling response to plyometric exercise in young ...
NSAIDs do not prevent exercise-induced performance ...Taken together, these data indicate that the plyometric exercise caused muscle soreness, but no NSAIDs improved muscle soreness 4- or 24-h post-exercise.
INFLUENCE OF A LOW-DOSE COX-2 INHIBITOR DRUG ...Our results indicate that celecoxib use following exercise does not alleviate inflammation, muscle damage, or oxidative stress.
A single, maximal dose of celecoxib, ibuprofen, or ...NSAIDs do not prevent exercise-induced performance deficits or alleviate muscle soreness: A placebo-controlled randomized, double-blinded, cross ...
Muscle soreness and rhabdomyolysisThe soreness that commonly follows unaccustomed and strenuous exercise is unlikely to be due to inflammation of the muscles.
SAFETY DATA SHEETPrecautionary Statements: P201 - Obtain special instructions before use. P202 - Do not handle until all safety precautions have been read ...
SAFETY DATA SHEETUse personal protective equipment as required. Avoid dust formation. Keep people away from and upwind of spill/leak. Evacuate personnel to safe.
Safety Data SheetSafety Data Sheet acc. to OSHA HCS. Date of issue: 10/07/2025. Revision date 10/07/2025. Trade name: Celecoxib. (Contd. from page 6). 61.0.20. · Other adverse ...
CELEBREX celecoxib capsules Cardiovascular RiskCardiovascular Risk. • CELEBREX may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, ...
Celecoxib (oral route) - Side effects & dosageThis medicine may cause bleeding in your stomach or bowels. These problems can happen without warning signs. This is more likely if you or your ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security